REG - LungLife AI, INC - Result of Special Meeting

LungLife AIAnnouncement

21/03/2024 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240321:nRSU8390Ha&default-theme=true

RNS Number : 8390H  LungLife AI, INC  21 March 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH
AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION
PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

 

21 March 2024

LungLife AI, Inc.

 

(the "Company" or "LungLife")

 

Result of Special Meeting

 

LungLife AI, Inc. (AIM: LLAI), a developer of clinical diagnostic solutions
for the early detection of lung cancer, announces that at the Special Meeting
held earlier today, all resolutions proposed were duly passed by
shareholders. A summary of the voting results is shown below:

 

               For         Against  Withheld  Total Votes Cast  % Voting For*
 Resolution 1  19,992,507  20,006   0         20,012,513        78.45%
 Resolution 2  19,992,507  20,006   0         20,012,513        78.45%
 Resolution 3  19,992,507  20,006   0         20,012,513        78.45%
 Resolution 4  19,992,507  20,006   0         20,012,513        78.45%

* This column represents the number of votes that were cast for the
resolutions as a percentage of the total issued and outstanding shares of the
Company as at the record date for the meeting.

Accordingly, subject to admission of the New Shares to trading on AIM, the
Company has raised a total of £1.8 million (before expenses) via the Placing
and Subscription through the issue and allotment of 5,172,621 new Common
Shares. An application has been made for the New Shares to be admitted to
trading on AIM, which is expected to take place at 8.00 a.m. on 22 March 2024.

Unless otherwise defined in this announcement, capitalised terms used in this
announcement shall have the same meanings as defined in the Company's
announcement of 4 March 2024.

 

Enquiries:

 

 

 LungLife AI, Inc.                                         www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                          Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Joint Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Goodbody Stockbrokers UC (Joint Broker)                   Tel: +44 (0)20 3841 6202

 Tom Nicholson / Cameron Duncan / William Hall

 Walbrook PR Limited                                        Tel: +44 (0)20 7933 8780
 Paul McManus / Alice Woodings / Phillip Marriage          or LungLifeAI@walbrookpr.com (mailto:LungLifeAI@walbrookpr.com)

 

 

About LungLife AI Inc

 

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com) .

 

 

IMPORTANT NOTICES

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN
THEM, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION,
FORWARDING OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR
INTO THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE
OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED
STATES"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION
IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER,
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF
SECURITIES IN ANY JURISDICTION.

The securities referred to herein have not been and will not be registered
under the US Securities Act of 1933, as amended (the "Securities Act"), or
with any securities regulatory authority of any State or other jurisdiction of
the United States, and may not be offered, sold or transferred, directly or
indirectly, in or into the United States, or to or for the account or benefit
of US persons (as defined in Regulation S under the Securities Act
("Regulation S")), except pursuant to an exemption from, or in a transaction
not subject to, the registration requirements of the Securities Act and in
compliance with the securities laws of any State or any other jurisdiction of
the United States.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMUARSRSSUOUAR